Advances in the development of KRAS inhibitors
Pasi Jänne, MD, PhD, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, discusses the latest developments in targeting KRAS-mutant cancers. The approval of sotorasib and adagrasib for patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) has made a significant impact on the treatment landscape. Current KRAS inhibitors may also have potential in gastrointestinal cancers, where G12D inhibitors can target certain subtypes of pancreatic cancer. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Видео Advances in the development of KRAS inhibitors канала VJOncology
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Видео Advances in the development of KRAS inhibitors канала VJOncology
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BCOPERA: contact X-ray brachytherapy in addition to CRT in organ preservation for rectal cancerAMBER: cobolimab monotherapy & in combination with PD-1 inhibitors nivolumab or dostarlimabReal-world toxicities associated with lorlatinib in ALK+ NSCLCWhat to do in patients with early-stage TNBC who have not achieved a pCR?Current treatment recommendations and future directions for EGFR-mutant NSCLCDoes every patient with localized muscle-invasive bladder cancer need a cystectomy?The future of immunotherapy in melanomaBias and microaggressions in healthcareUpcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091Exciting updates from ASCO 2022 in the anti-EGFR rechallenge space for colorectal cancerLong-term outcomes of DSNB for cN0 penile cancerKidney cancer: post-surgery sorafenibImmunotherapy & local ablative therapy in mCRC with liver metastasesThe role of dendritic cells in eliciting an anti—tumor immune responseNRG-HN002: chemoradiotherapy for p16-positive low-risk HPV-associated oropharyngeal carcinomaFacial plastic surgery after skin cancerHER2DX and pCR in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studiesStrategies to improve the response to immunotherapy in TNBCLatest developments in immunotherapy for advanced/recurrent endometrial cancer